| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H26O3 |
| Molecular Weight | 326.4293 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)[C@H]1CC[C@H](CC2=C(O)C(=O)C3=CC=CC=C3C2=O)CC1
InChI
InChIKey=KLLIVCPQDTYMLC-HDJSIYSDSA-N
InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,13-14,24H,8-12H2,1-3H3/t13-,14-
| Molecular Formula | C21H26O3 |
| Molecular Weight | 326.4293 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Buparvaquone is a second-generation hydroxynaphtaquinone with novel features that make it an effective compound for the therapy and prophylaxis of all forms of theileriosis. It has shown promising activities against Leishmania spp. and Neospora caninum infection. In combination with arteether it is effective against Babesia equi. Buparvaquone directly inhibits the respiration of Theileria parasites. Due to the inhibiting effects of theileriosis on the immune system, vaccination should be delayed until the animal has recovered from theileriosis. Localised, painless, oedematous swelling may occasionally be seen at the injection site.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Cattle: A single dose of 1 ml per 20 kg body weight. (2.5 mg buparvaquone/kg body weight). In severe and advanced cases, a second treatment may be required at 48-72 hrs after the initial injection at the same dose rate.
Route of Administration:
Intramuscular
